產品分類

            Products

            產品中心/ PRODUCTS

            我的位置:首頁  >  產品中心  >    >  動物活體成像設備  >  腫瘤測量儀

            腫瘤測量儀

            • 更新時間:2024-10-11
            • 訪  問  量:1158

            簡要描述:動物腫瘤測量儀,非常適合對大鼠小鼠等動物的皮下腫瘤進行快速測量、分析,精確測量動物腫瘤并對腫瘤信息存檔與跟蹤

            在線咨詢

            聯系電話:021-54377179

            產品詳情

            動物腫瘤測量儀,非常適合對大鼠小鼠等動物的皮下腫瘤進行快速測量、分析,精確測量動物腫瘤并對腫瘤信息存檔與跟蹤。


            主要技術參數: 

            · 測量范圍:0-25mm腫瘤尺寸:20*20*20mm
            · 3D測量精確度:<0.3mm
            · 圖像捕捉時間:0.1s
            · 接口:USB 2.0
            · 相機:1600*1200 像素(2MP)
            · 工作距離:50mm


            動物腫瘤測量分析儀的主要特點: 
            · 手持式成像裝置,實現立體成像;
            · 適合測量不同尺寸的腫瘤;
            · 方便使用:觸屏式電腦,操作方便;
            · 內置軟件,自動計算腫瘤尺寸,跟蹤整個實驗進展。 
              

            · 快速,高效,保證了高通量和可靠測量;
            · 全自動測量跟蹤系統;
            · 實時數據分析與處理。 


                 
              
             


            部分用戶: 

            Hunter College, CUNY

            Vanderbilt University Medical Center

            Hainan Medical University

            Howard Hughes Medical Institute

            Memorial Sloan Kettering Cancer Center

            Cancer Center Amsterdam

            GlaxoSmithKline

            Imec

            K.U.Leuven

            Neuro-Electronics Research Flanders

            Pepric

            PharmaVize

            reMYND

            University Ghent

            SEPS Pharma

            Vlaams Instituut voor Biotechnologie

            University Antwerp

            ThromboGenics

            Janssen Pharmaceutica

            City University of Hong Kong


            參考文獻:

            1.Adams EJ, Karthaus WR, Hoover E, et al. FOXA1 mutations alter pioneering activity, differentiation and prostate cancer phenotypes. Nature. 2019;571(7765):408-412. doi:10.1038/s41586-019-1318-9.
            2.Zhang Z, Zhou C, Li X, et al. Loss of CHD1 Promotes Heterogeneous Mechanisms of Resistance to AR-Targeted Therapy via Chromatin Dysregulation. Cancer Cell. 2020;37(4):584-598.e11. doi:10.1016/j.ccell.2020.03.001.
            3.Santich BH, Park JA, Tran H, et al. Interdomain spacing and spatial configuration drive the potency of IgG-[L]-scFv T cell bispecific antibodies. Sci Transl Med. 2020;12(534):eaax1315. doi:10.1126/scitranslmed.aax1315.
            4.Park JA, Xu H, Cheung, I, et al. Abstract B38: Tetravalent bispecific antibodies specific for HER2 and disialoganglioside GD2 to engage polyclonal T cells for osteosarcoma therapy. Cancer Res. 2018;78(19),B38.doi:10.1158/1538-7445.PEDCA17-B38.
            5.Wu CF, Wu CY, Lin CF, et al. The anticancer effects of cyanidin 3-O-glucoside combined with 5-fluorouracil on lung large-cell carcinoma in nude mice. Biomed Pharmacother. 2022;151:113128. doi:10.1016/j.biopha.2022.113128.
            6.Wang L, Hoseini SS, Xu H, et al. Silencing Fc Domains in T cell-Engaging Bispecific Antibodies Improves T-cell Trafficking and Antitumor Potency. Cancer Immunol Res. 2019;7(12):2013-2024. doi:10.1158/2326-6066.CIR-19-0121.
            7.Grochowska A, Statkiewicz M, Kulecka M, et al. Evidence supporting the oncogenic role of BAZ1B in colorectal cancer. Am J Cancer Res. 2022;12(10):4751-4763. 
            8.Hoseini SS, Vadlamudi M, Espinosa-Cotton M, et al. T cell engaging bispecific antibodies targeting CD33 IgV and IgC domains for the treatment of acute myeloid leukemia. J Immunother Cancer. 2021;9(5):e002509. doi:10.1136/jitc-2021-002509.
            9.Beguin E, Gray MD, Logan KA, et al. Magnetic microbubble mediated chemo-sonodynamic therapy using a combined magnetic-acoustic device. J Control Release. 2020;317:23-33. doi:10.1016/j.jconrel.2019.11.013.
            10.Mao N, Gao D, Hu W, et al. Aberrant Expression of ERG Promotes Resistance to Combined PI3K and AR Pathway Inhibition through Maintenance of AR Target Genes. Mol Cancer Ther. 2019;18(9):1577-1586. doi:10.1158/1535-7163.MCT-18-1386.
            11.Wu Z, Guo HF, Xu H, et al. Development of a Tetravalent Anti-GPA33/Anti-CD3 Bispecific Antibody for Colorectal Cancers. Mol Cancer Ther. 2018;17(10):2164-2175. doi:10.1158/1535-7163.MCT-18-0026.
            12.Poty S, Mandleywala K, O'Neill E, et al. 89Zr-PET imaging of DNA double-strand breaks for the early monitoring of response following α- and β-particle radioimmunotherapy in a mouse model of pancreatic ductal adenocarcinoma. Theranostics. 2020;10(13):5802-5814. doi:10.7150/thno.44772.
            13.Hoseini SS, Guo H, Wu Z, et al. A potent tetravalent T-cell-engaging bispecific antibody against CD33 in acute myeloid leukemia. Blood Adv. 2018;2(11):1250-1258. doi:10.1182/bloodadvances.2017014373.
            14.Zhang Z, Karthaus WR, Lee YS, et al. Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell. 2020;38(2):279-296.e9. doi:10.1016/j.ccell.2020.06.005.
            15.Poty S, Carter LM, Mandleywala K, et al. Leveraging Bioorthogonal Click Chemistry to Improve 225Ac-Radioimmunotherapy of Pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2019;25(2):868-880. doi:10.1158/1078-0432.CCR-18-1650.




                

                

                :,

                     

                :

                yuyanbio

                :yuyanbio

                

            在線咨詢

            留言框

            • 產品:

            • 您的單位:

            • 您的姓名:

            • 聯系電話:

            • 常用郵箱:

            • 省份:

            • 詳細地址:

            • 補充說明:

            • 驗證碼:

              請輸入計算結果(填寫阿拉伯數字),如:三加四=7
            上海玉研科學儀器有限公司
            地址:上海市閔行區興梅路485號眾欣大廈506室
            郵箱:sales@yuyanbio.com
            傳真:021-35183767
            掃一掃關注我們
            SCAN
            主站蜘蛛池模板: 景洪市| 高安市| 巩义市| 渭南市| 承德市| 兰坪| 江达县| 鄱阳县| 集贤县| 蚌埠市| 怀集县| 工布江达县| 姜堰市| 敦化市| 察哈| 张家口市| 通河县| 土默特右旗| 三明市| 江西省| 太仓市| 新河县| 固原市| 宽甸| 始兴县| 樟树市| 宁河县| 清远市| 玉山县| 永善县| 淮北市| 门源| 蒙阴县| 清水河县| 阳东县| 铜梁县| 略阳县| 四子王旗| 莆田市| 莱西市| 楚雄市|